Table 2. Characteristics of patients with accompanying NME according to pathologic results.
| Positive (n = 22) | Negative (n = 18) | P-value | |
|---|---|---|---|
| Age (y) | 53.0±8.1 | 55.8±10.0 | .262 |
| Age category | |||
| <50 years | 7 (31.8) | 6 (33.3) | .999 |
| ≥ 50 years | 15 (68.2) | 12 (66.7) | |
| MR finding | |||
| Index mass size (cm) | 2.3 ± 1.0 | 2.2 ± 0.7 | .748 |
| Total extent with NME (cm) | 4.7 ± 1.3 | 4.3 ± 0.8 | .351 |
| Background parenchymal enhancement | |||
| Minimal | 12 (54.5) | 12 (66.7) | .687 |
| Mild | 6 (27.3) | 3 (16.7) | |
| Moderate | 4 (18.2) | 3 (16.7) | |
| Distribution of NME | |||
| Focal | 5 (22.7) | 3 (16.7) | .499 |
| Linear | 4 (18.2) | 5 (27.8) | |
| Segmental | 11 (50.0) | 6 (33.3) | |
| Regional | 2 (9.1) | 4 (22.2) | |
| Enhancement of NME | |||
| Homogeneous | 1 (4.5) | 4 (22.2) | .056 |
| Heterogeneous | 17 (77.3) | 14 (77.8) | |
| Clumped | 4 (18.2) | 0 (0) | |
| Histopathologic result | |||
| Invasive carcinoma size (cm) | 2.5 ± 1.4 | 2.0 ± 0.7 | .158 |
| Estrogen receptor status | |||
| Positive | 15 (68.2) | 11 (61.1) | .744 |
| Negative | 7 (31.8) | 7 (38.9) | |
| Progesterone receptor status | .525 | ||
| Positive | 9 (40.9) | 10 (55.6) | |
| Negative | 13 (59.1) | 8 (44.4) | |
| HER2 receptor status | .016 | ||
| Positive | 11 (50) | 2 (11.1) | |
| Negative | 11 (50) | 16 (88.9) |